Ionis Pharmaceuticals, Inc. Announces Advisory Services Agreement with Richard Geary

Details

entered into an Advisory Services Agreement with Dr. Richard Geary, who will provide advisory services to the company following his retirement in January 2026. The agreement, which is effective from January 16, 2026, and extends through February 13, 2027, will pay Dr. Geary a total fee of up to $450,000 based on the hours of advisory services rendered.

Items reported

Exhibits (1)

About Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.